1378P Biopsy-based basal-luminal subtyping classifier in high-risk prostate cancer: Analysis of the NRG Oncology/RTOG 9202, 9413, and 9902 randomized phase III trials

Abstract

Subtype differentiation in prostate cancer (PCa) has been shown to be prognostic and predictive of androgen deprivation therapy (ADT) response in the postoperative setting. We sought to determine whether basal-luminal subtypes based on gene expression profiling of pretreatment biopsy samples would be predictive for the benefit of long- (LT; 24-28 months) vs short-term (ST; 4 months) ADT, hypothesizing that patients with basal tumors benefit more from longer term ADT.